June 4, 2025 - 00:01

The financial results for the first quarter ending April 30, 2025, reveal significant growth and robust performance. The company reported a revenue of $330.8 million, marking a 15% increase from $287.6 million during the same period last year. This upward trend is indicative of strong market demand and effective operational strategies.
Net income surged to $53.9 million, representing an impressive 87% increase compared to $28.8 million in the first quarter of the previous fiscal year. The non-GAAP net income also saw a notable rise, reaching $85.8 million, a 22% increase from $70.3 million in the prior year’s quarter.
Earnings per diluted share reflected this positive trajectory, with net income per diluted share climbing to $0.61, an 85% increase from $0.33 in Q1 FY25. Non-GAAP net income per diluted share also increased to $0.97, a 21% rise from $0.80 in the same quarter last year. These results underscore the company's strong financial health and commitment to growth.
May 17, 2026 - 08:31
How Investors Are Reacting To NVE (NVEC) Steady Earnings And Maintained Quarterly DividendNVE Corporation has released its full-year results for the period ending March 31, 2026, posting revenue of US$26.33 million and net income of US$15.2 million. The company also confirmed a...
May 16, 2026 - 22:25
Risky Integration or Rewarding Returns? The Stakes of SoundHound's LivePerson Acquisition.SoundHound AI`s acquisition of LivePerson is drawing mixed reactions from investors, with the immediate fallout hitting the stock price. The deal, which combines SoundHound`s voice AI technology...
May 16, 2026 - 10:38
Bank of Hawaii, Glacier Bancorp, and Wintrust Financial Shares Plummet, What You Need To KnowShares of several regional banks took a sharp hit in afternoon trading Wednesday after the latest inflation report came in hotter than expected. The April Consumer Price Index rose 3.8%, a figure...
May 15, 2026 - 17:39
Plus Therapeutics Shares First Quarter 2026 Financial Results and Updates on REYOBIQ and CNSide ProgressHOUSTON, May 15, 2026 -- Plus Therapeutics, a healthcare company focused on precision diagnostics and radiopharmaceuticals for central nervous system cancers, reported its financial results for the...